Hepatitis C Virus Clinical Trial
Official title:
A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India
| Verified date | May 2018 |
| Source | Gilead Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study will evaluate the safety and efficacy of sofosbuvir (SOF)-based regimens administered as per the approved prescribing information in adults with chronic hepatitis C virus (HCV) infection treated in routine clinical practice in India.
| Status | Completed |
| Enrollment | 532 |
| Est. completion date | April 23, 2018 |
| Est. primary completion date | November 30, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - HCV-infected patients living in India - Treatment with a SOF-based regimen as determined by the patient's treating physician per the approved prescribing information. - Patients who provide written and signed informed consent prior to initiation of treatment where required. Exclusion Criteria: - Concurrent participation in an HCV clinical trial (except trials not testing investigational medicinal products) - Patients presenting a risk of not being able to be followed (eg, patients planning to move or leave the country in a foreseeable future) |
| Country | Name | City | State |
|---|---|---|---|
| India | Sanjivani Superspeciality Hospital Clinical Research Department | Ahmedabad | |
| India | Saviour Hospital | Ahmedabad | |
| India | BGS global Hospitals | Bengaluru | Karnataka |
| India | Manipal Hospital | Bengaluru | Karnataka |
| India | Postgraduate Institute of Medical Education and Research | Chandigarh | UT |
| India | Global Hospitals & Health City | Chennai | Tamil Nadu |
| India | Sri Ramachandra Medical College and Research | Chennai | |
| India | VGM Hospital | Coimbatore | Tamil Nadu |
| India | Artemis Hospital | Gurgaon | Haryana |
| India | Aware Global Hospital | Hyderabad | |
| India | Global Hospitals | Hyderabad | Andhra Pradesh |
| India | Marudhar Hospital | Jaipur | Rajasthan |
| India | S.R. Kalla Memorial Gastro & General Hospital | Jaipur | Rajasthan |
| India | SMS Medical College & Hospital | Jaipur | Rajasthan |
| India | Lakeshore Hospital | Kochi | Kerala |
| India | Institute of Post Graduate Medical Education And Research | Kolkata | West Bengal |
| India | K. R. M. Hospital & Research Centre | Lucknow | |
| India | KGMU Medical College | Lucknow | Uttar Pradesh |
| India | M.V. Hospital and Research Centre | Lucknow | |
| India | Dayanand Medical College & Hospital | Ludhiana | |
| India | BYL Nair Hospital & T N Medical College | Mumbai | |
| India | Midas Institute of Gastro-enterology | Nagpur | Maharashtra |
| India | A.I.I.M.S. | New Delhi | Ansari Nagar |
| India | Sir Ganga Ram Hospital | New Delhi | |
| India | Nirmal Hospital Pvt. Ltd. | Surat | Gujarat |
| India | Om Research Center, Om Surgical Center & Maternity Home | Varanasi |
| Lead Sponsor | Collaborator |
|---|---|
| Gilead Sciences |
India,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence of adverse drug reactions (ADRs) during treatment and up to 4 weeks after discontinuation of a SOF-based regimen | Up to Posttreatment Week 4 | ||
| Secondary | Proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12) | SVR12 is defined as HCV RNA < the lower limit of quantification (LLOQ) 12 weeks following the last dose of study drug, respectively. | Posttreatment Week 12 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02907996 -
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
|
||
| Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
| Not yet recruiting |
NCT02893046 -
HCV Care Pathway in Ile-de-France
|
N/A | |
| Completed |
NCT01428063 -
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
|
Phase 2 | |
| Completed |
NCT01396005 -
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
|
Phase 1 | |
| Completed |
NCT01195181 -
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
|
Phase 4 | |
| Completed |
NCT00219999 -
Hepatitis C Virus and the Humoral Immune System
|
N/A | |
| Completed |
NCT02243293 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
|
Phase 2/Phase 3 | |
| Completed |
NCT02265237 -
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
|
Phase 3 | |
| Not yet recruiting |
NCT06104046 -
Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis
|
||
| Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
| Withdrawn |
NCT00947245 -
Japanese Bridging Study Conducted in the United States
|
Phase 1 | |
| Completed |
NCT01713283 -
Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
| Completed |
NCT01458535 -
A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
|
Phase 2 | |
| Completed |
NCT01479881 -
A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus
|
Phase 1 | |
| Completed |
NCT01193361 -
Ph IIA Study (SOC +/- NS5B)
|
Phase 2 | |
| Completed |
NCT01241773 -
TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir
|
Phase 1 | |
| Completed |
NCT01006031 -
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
|
Phase 2/Phase 3 | |
| Completed |
NCT00819026 -
Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors
|
N/A | |
| Completed |
NCT00382798 -
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
|
Phase 1/Phase 2 |